Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
Author:
Affiliation:
1. Department of Pharmacology and Therapeutics , Seth G.S. Medical College & KEM Hospital, Parel , Mumbai , India
2. Women and Child Development Commissionerate, Government of Maharashtra , Pune , India
Publisher
Walter de Gruyter GmbH
Subject
Drug Discovery,Pharmacology,General Medicine,Physiology
Link
https://www.degruyter.com/document/doi/10.1515/jbcpp-2023-0234/pdf
Reference17 articles.
1. Sun, H, Saeedi, P, Karuranga, S, Pinkepank, M, Ogurtsova, K, Duncan, BB, et al.. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119.
2. Rangaswami, J, Bhalla, V, De Boer, IH, Staruschenko, A, Sharp, JA, Singh, RR, et al.. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation 2020;142:e265–86. https://doi.org/10.1161/CIR.0000000000000920.
3. Nauck, MA, Quast, DR, Wefers, J, Meier, JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.
4. Seetharaman, R, Pandit, S, Joshi, SS. The prospective record-breaking obesity drug tirzepatide raises concerns about affordability. J Basic Clin Physiol Pharmacol 2023;34:549–50. https://doi.org/10.1515/jbcpp-2023-0129.
5. Karakasis, P, Patoulias, D, Pamporis, K, Stachteas, P, Bougioukas, KI, Klisic, A, et al.. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism 2023;149:155710. https://doi.org/10.1016/j.metabol.2023.155710.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3